SEMA3C and breast carcinoma: We found SEMA3C’s mRNA expression to be the highest in ER+/HER2− breast cancer patients when compared to all other subtypes, including HER2+ and Triple-Negative breast cancer (p < 0.0001) (Figure 1A).